Becton, Dickinson and Company (NYSE:BDX) Shares Purchased by Atlas Capital Advisors Inc.

Atlas Capital Advisors Inc. boosted its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 28,500.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,860 shares of the medical instruments supplier's stock after purchasing an additional 2,850 shares during the period. Atlas Capital Advisors Inc.'s holdings in Becton, Dickinson and Company were worth $649,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Bank of Jackson Hole Trust bought a new position in Becton, Dickinson and Company in the fourth quarter worth approximately $25,000. Sierra Ocean LLC bought a new stake in Becton, Dickinson and Company during the fourth quarter valued at about $29,000. Picton Mahoney Asset Management increased its position in Becton, Dickinson and Company by 61.4% in the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock worth $32,000 after buying an additional 54 shares in the last quarter. Hopwood Financial Services Inc. bought a new stake in Becton, Dickinson and Company during the 4th quarter worth approximately $39,000. Finally, Versant Capital Management Inc raised its position in shares of Becton, Dickinson and Company by 54.1% during the 4th quarter. Versant Capital Management Inc now owns 208 shares of the medical instruments supplier's stock valued at $47,000 after purchasing an additional 73 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

BDX has been the subject of a number of analyst reports. Piper Sandler increased their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an "overweight" rating in a research note on Tuesday, January 28th. StockNews.com upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Wednesday, April 2nd. Finally, Barclays lowered their price target on Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating on the stock in a report on Monday. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $275.71.

Remove Ads

Insider Buying and Selling

In other news, EVP Richard Byrd sold 459 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $230.00, for a total transaction of $105,570.00. Following the transaction, the executive vice president now owns 6,952 shares of the company's stock, valued at approximately $1,598,960. This represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Bertram L. Scott sold 700 shares of the firm's stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total value of $159,593.00. Following the sale, the director now directly owns 36,033 shares of the company's stock, valued at $8,215,163.67. This represents a 1.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 4,196 shares of company stock worth $962,685 over the last three months. 0.36% of the stock is owned by insiders.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX traded down $6.36 during midday trading on Wednesday, reaching $194.47. 839,493 shares of the stock traded hands, compared to its average volume of 1,662,054. The company's 50 day moving average is $227.28 and its 200 day moving average is $230.68. Becton, Dickinson and Company has a one year low of $193.14 and a one year high of $251.99. The stock has a market capitalization of $55.84 billion, a PE ratio of 32.27, a P/E/G ratio of 1.63 and a beta of 0.35. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, topping analysts' consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. On average, equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, March 31st. Investors of record on Monday, March 10th were given a $1.04 dividend. The ex-dividend date was Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 2.14%. Becton, Dickinson and Company's dividend payout ratio is presently 69.10%.

Becton, Dickinson and Company announced that its board has approved a stock repurchase plan on Tuesday, January 28th that allows the company to repurchase 10,000,000 shares. This repurchase authorization allows the medical instruments supplier to buy shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's board believes its stock is undervalued.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.